A critical function for type I interferons in cancer immunoediting (original) (raw)

• Shankaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
  Article CAS Google Scholar
• Dunn, G.P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998 (2002).
  Article CAS Google Scholar
• Dunn, G.P., Old, L.J. & Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004).
  Article CAS Google Scholar
• Dunn, G.P., Old, L.J. & Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137–148 (2004).
  Article CAS Google Scholar
• Dighe, A.S., Richards, E., Old, L.J. & Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1, 447–456 (1994).
  Article CAS Google Scholar
• Kaplan, D.H. et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556–7561 (1998).
  Article CAS Google Scholar
• Ikeda, H., Old, L.J. & Schreiber, R.D. The roles of IFN-γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95–109 (2002).
  Article CAS Google Scholar
• Mumberg, D. et al. CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96, 8633–8638 (1999).
  Article CAS Google Scholar
• Fallarino, F. & Gajewski, T.F. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J. Immunol. 163, 4109–4113 (1999).
  CAS PubMed Google Scholar
• Gresser, I. et al. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158, 2095–2107 (1983).
  Article CAS Google Scholar
• Gresser, I., Bandu, M.T. & Brouty-Boye, D. Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. J. Natl. Cancer Inst. 52, 553–559 (1974).
  Article CAS Google Scholar
• Affabris, E. et al. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. Haematologica 72, 76–78 (1987).
  CAS PubMed Google Scholar
• Gresser, I. et al. Antibody to mouse interferon α/β abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J. Exp. Med. 168, 1271–1291 (1988).
  Article CAS Google Scholar
• Belardelli, F., Ferrantini, M., Proietti, E. & Kirkwood, J.M. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 119–134 (2002).
  Article CAS Google Scholar
• Qin, Z., Kim, H.J., Hemme, J. & Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon-γ receptor-dependent foreign body reaction. J. Exp. Med. 195, 1479–1490 (2002).
  Article CAS Google Scholar
• Dighe, A.S., Farrar, M.A. & Schreiber, R.D. Inhibition of cellular responsiveness to interferon-γ (IFN-γ) induced by overexpression of inactive forms of the IFN-γ receptor. J. Biol. Chem. 268, 10645–10653 (1993).
  CAS PubMed Google Scholar
• Qin, Z. & Blankenstein, T. CD4+ T Cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 12, 677–686 (2000).
  Article CAS Google Scholar
• Le Bon, A. & Tough, D.F. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14, 432–436 (2002).
  Article CAS Google Scholar
• Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249–1255 (1999).
  Article CAS Google Scholar
• Montoya, M. et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263–3271 (2002).
  Article CAS Google Scholar
• Le Bon, A. et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009–1015 (2003).
  Article CAS Google Scholar
• Le Bon, A. et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461–470 (2001).
  Article CAS Google Scholar
• Wu, J. & Lanier, L.L. Natural killer cells and cancer. Adv. Cancer Res. 90, 127–156 (2003).
  Article CAS Google Scholar
• Sato, K. et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31, 3138–3146 (2001).
  Article CAS Google Scholar
• Marrack, P., Kappler, J. & Mitchell, T. Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521–530 (1999).
  Article CAS Google Scholar
• Zhang, X. et al. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8, 591–599 (1998).
  Article CAS Google Scholar
• Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516–523 (2003).
  Article CAS Google Scholar
• Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323–331 (1997).
  Article CAS Google Scholar
• Tough, D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk. Lymphoma 45, 257–264 (2004).
  Article CAS Google Scholar
• Colonna, M., Krug, A. & Cella, M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14, 373–379 (2002).
  Article CAS Google Scholar
• Colonna, M., Trinchieri, G. & Liu, Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5, 1219–1226 (2004).
  Article CAS Google Scholar
• Taniguchi, T. & Takaoka, A. A weak signal for strong responses: interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2, 378–386 (2001).
  Article CAS Google Scholar
• Soos, J.M. & Szente, B.E. Type I interferons. in The Cytokine Handbook Vol. 1 (eds. Lotz, M.T. & Thomson, A.W.) 549–566 (Academic Press, 2003).
  Chapter Google Scholar
• Enzler, T. et al. Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J. Exp. Med. 197, 1213–1219 (2003).
  Article CAS Google Scholar
• Lesinski, G.B. et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112, 170–180 (2003).
  Article CAS Google Scholar
• Belardelli, F., Gresser, I., Maury, C. & Maunoury, M.T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int. J. Cancer 30, 813–820 (1982).
  Article CAS Google Scholar
• Afkarian, M. et al. T-bet is a STAT1-induced regulator of IL-12R expression in naive CD4+ T cells. Nat. Immunol. 3, 549–557 (2002).
  Article CAS Google Scholar
• Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258–1266 (1999).
  Article CAS Google Scholar
• Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735–1737 (1999).
  Article CAS Google Scholar
• Sheehan, K.C. et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 181, 607–617 (1995).
  Article CAS Google Scholar
• Kondo, M. et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21, 759–806 (2003).
  Article CAS Google Scholar
• Pear, W.S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792 (1998).
  CAS PubMed Google Scholar